Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Receivables (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Receivables for 7 consecutive years, with $96.8 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 16.56% to $96.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.8 million through Dec 2025, up 16.56% year-over-year, with the annual reading at $96.8 million for FY2025, 16.56% up from the prior year.
  • Receivables hit $96.8 million in Q4 2025 for Harmony Biosciences Holdings, down from $100.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $106.0 million in Q1 2025 to a low of $23.6 million in Q1 2021.
  • Historically, Receivables has averaged $65.1 million across 5 years, with a median of $65.5 million in 2023.
  • Biggest five-year swings in Receivables: skyrocketed 103.39% in 2021 and later increased 11.81% in 2025.
  • Year by year, Receivables stood at $34.8 million in 2021, then soared by 57.1% to $54.7 million in 2022, then surged by 35.44% to $74.1 million in 2023, then grew by 11.99% to $83.0 million in 2024, then rose by 16.56% to $96.8 million in 2025.
  • Business Quant data shows Receivables for HRMY at $96.8 million in Q4 2025, $100.7 million in Q3 2025, and $93.0 million in Q2 2025.